Cited by 14Retinal Development and DisordersVirus-based gene therapy researchRNA Interference and Gene Delivery

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The Opportunities and Challenges of Gene Therapy for Treatment of Inherited Forms of Vision and Hearing Loss

Open access
Simons, Emmanuel J., Trapani, Ivana·2023·Human Gene Therapy

Abstract

Inherited forms of blindness and deafness are highly prevalent and severe conditions that significantly impact the lives of millions of people worldwide. The lack of therapeutic options for these conditions poses a major socioeconomic burden. Over the last decades, gene therapy has proven to be a life changing treatment for hereditary and acquired forms of diseases, and extensive preclinical investigation in animal models of both retinal and inner ear disorders has highlighted promising translational opportunities for these disorders too. This led to dozens of clinical trials investigating the efficiency of gene therapy-based approaches, with some of the products for retinal conditions successfully reaching phase III of development or even market authorization. However, challenges remain for the use of gene therapy, which are related to both the features of the delivery vehicles currently available and characteristics of the retinal and inner ear disorders targeted. Therefore, further developments in gene therapy platforms' design, including exploitation of novel technologies such as genome editing, RNA-targeted therapies, and optogenetics, are actively ongoing, driving the field forward. In this study, we review the ongoing applications and achievements of gene therapy for treatment of inherited forms of blindness and deafness as well as the developments that are being pursued in the field to overcome the current limitations.

Overview

Integrity signals

Registry

Crossref · 10.1089/hum.2023.126

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Gene therapy with AAV vectors is being widely explored for inherited retinal diseases given their ability to efficiently transduce photoreceptors and their good safety and efficacy profiles in humans.

    “Gene therapy with adeno-associated viral (AAV) vectors is being widely explored for treatment of inherited retinal diseases given their ability to efficiently transduce photoreceptors and their good safety and efficacy profiles in humans (4).”

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 67

  1. 10.1152/physrev.00035.2019 · DOI
  2. 10.3389/fgeed.2021.737632 · DOI
  3. 10.1016/j.preteyeres.2021.101029 · DOI
  4. 10.1038/s41576-023-00597-7 · DOI
  5. Cehajic-Kapetanovic J, 2022, Nat Biomed Eng, 1
  6. 10.1016/j.preteyeres.2014.08.001 · DOI
  7. 10.3389/fnins.2021.652215 · DOI
  8. FDA approves hereditary blindness gene therapy, 2018, Nat Biotechnol, 36
  9. Mendes BB, 2022, Nat Rev Methods Prim, 2, 1, 10.1038/s43586-021-00091-6 · DOI
  10. 10.1038/s41573-019-0012-9 · DOI · Paper page
  11. Bulcha JT, 2021, Signal Transduct Target Ther, 6, 1, 10.1038/s41392-021-00487-6 · DOI · Paper page
  12. 10.2147/TACG.S383453 · DOI · Paper page
  13. 10.1016/j.coviro.2014.07.008 · DOI
  14. 10.1016/j.heares.2020.108092 · DOI
  15. 10.1016/j.molmed.2018.06.006 · DOI · Paper page
  16. 10.1016/j.preteyeres.2018.08.003 · DOI
  17. 10.1055/a-1384-0818 · DOI
  18. 10.1016/j.visres.2023.108258 · DOI
  19. 10.1167/iovs.64.7.39 · DOI · Paper page
  20. 10.15252/emmm.201809396 · DOI · Paper page
  21. 10.1073/pnas.1817537116 · DOI · Paper page
  22. 10.1016/j.cell.2006.08.040 · DOI
  23. 10.1055/s-0041-1730410 · DOI
  24. 10.3390/jcm12031046 · DOI
  25. 10.1016/j.ymthe.2023.02.001 · DOI
  26. 10.1097/MOP.0000000000001273 · DOI
  27. 10.1007/s10162-022-00866-y · DOI
  28. 10.3389/fnins.2023.1177791 · DOI
  29. 10.1038/s41598-021-81093-y · DOI
  30. 10.1007/s00439-016-1648-8 · DOI
  31. 10.1016/j.preteyeres.2022.101110 · DOI · Paper page
  32. 10.1177/25158414221134602 · DOI
  33. Leroy BP, 2022, Invest Ophthalmol Vis Sci, 63, 4536
  34. 10.26508/lsa.202201592 · DOI
  35. 10.1038/s41581-022-00636-2 · DOI
  36. 10.1126/science.abb1400 · DOI
  37. 10.1038/s41589-021-00868-6 · DOI
  38. 10.1038/mt.2015.220 · DOI
  39. 10.1089/crispr.2021.0141 · DOI
  40. 10.1038/s41433-022-02169-1 · DOI
  41. Tan E, 2001, Investig Ophthalmol Vis Sci, 42, 589
  42. 10.1073/pnas.96.2.736 · DOI
  43. 10.1038/s41467-022-29550-8 · DOI
  44. 10.1038/nature20565 · DOI · Paper page
  45. 10.1038/s41467-019-14181-3 · DOI
  46. 10.1038/s41591-018-0327-9 · DOI · Paper page
  47. 10.1038/nature25164 · DOI · Paper page
  48. 10.1038/s41591-019-0500-9 · DOI
  49. 10.1016/j.omtn.2022.07.016 · DOI
  50. 10.7150/thno.67781 · DOI
  51. 10.1016/j.celrep.2022.111061 · DOI
  52. 10.1038/s41551-019-0501-5 · DOI
  53. 10.1038/s41551-020-00632-6 · DOI
  54. 10.1016/j.ymthe.2021.07.011 · DOI · Paper page
  55. 10.1016/j.ymthe.2023.06.007 · DOI
  56. 10.1038/s41551-021-00788-9 · DOI
  57. Kuang J, 2021, Methods, 194
  58. 10.1038/s41551-022-00911-4 · DOI
  59. 10.1089/genbio.2022.0015 · DOI
  60. 10.1089/hum.2019.220 · DOI · Paper page
  61. 10.1093/protein/gzu028 · DOI · Paper page
  62. 10.1016/j.preteyeres.2022.101065 · DOI
  63. 10.1016/j.preteyeres.2022.101089 · DOI
  64. 10.1016/j.neuron.2006.02.026 · DOI
  65. 10.1016/j.omtm.2020.06.019 · DOI
  66. 10.1016/j.omtm.2018.06.006 · DOI · Paper page
  67. 10.1016/j.visres.2023.108192 · DOI

Cited by

Sorted by citations

Metadata

Authors
Simons, E. J., & Trapani, I.
Affiliations
  • Akouos, Inc., Boston, Massachusetts, USA.
  • Federico II University Hospital (IT)
Corresponding author
Trapani, Ivana
Venue
Human Gene Therapy
Published
2023-09-01
Volume
34
Issue
17-18
Pages
808-820
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W4386246621
Cited by
14
References
4
Citations by year
2026: 1 · 2025: 5 · 2024: 7 · 2023: 1
FWCI
0.37
Type
journal article
Language
en
Open access
Locations
  • Human Gene Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
gene therapy, inherited blindness, hereditary hearing loss, retinal disease, inner ear disorders, gene delivery vectors, genome editing, RNA-targeted therapeutics, optogenetics, clinical trials, translational research
MeSH terms
Animals, Blindness, Deafness, Genetic Therapy, Hearing Loss, Deaf-Blind Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review